GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round

Entrada Therapeutics Announces Closing of Intitial Public Offering

Jasper Therapeutics Closes Transaction With Amplitude Healthcare Creating a Publicly Traded Biotechnology Company

Tango Therapeutics, Inc.closes merger with BCTG Acquisition Corp

Tempest Closes Merger with Millendo and Completes PIPE Financing

23andMe Successfully Closes its Business Combination with VG Acquisition Corp.

Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

Soteria Biotherapeutics launches with USD42 Million Series A Financing led by Roche Venture Fund and 5AM Ventures

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation

Eloxx Pharmaceuticals Acquires Zikani Therapeutics

Merck Completes Acquisition of Pandion Therapeutics

Enthera Pharmaceuticals extends Series A financing, raising a total of €35 million

Enliven Therapeutics Launches With Vision Of Advancing Medicine And Restoring Lives

Aligos Therapeutics announces Pricing of Initial Public Offering

C4 Therapeutics announces Pricing of an Upsized Initial Public Offering

Palladio Biosciences completes USD20 Million Series B Financing

BCTG Acquisition Corp. Announces Pricing of Upsized $145 Million Initial Public Offering

Vaxcyte Announces Pricing of Upsized Initial Public Offering

Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use

Jasper Therapeutics Announces Expansion of Series A Financing, Bringing Total Corporate Fundraising to More than $50 Million

Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

Black Diamond Therapeutics Closes $85 Million Series C Financing

NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases

Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)

Freenome Closes $160 Million Series B Financing to Advance Its Multiomics Blood Testing Platform for Early Cancer Detection

Purigen Biosystems Raises $26.4 Million Series B Financing to Accelerate Commercialization of Automated Sample Preparation Platform

IDEAYA Announces Pricing of Initial Public Offering

Arch Oncology Raises $50 Million Series B Financing

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics

Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform

Tempest and Millendo Announce Proposed Merger Agreement

Allakos announces Pricing of Initial Public Offering

Roche joins Intel & iSeed as investors in Care Innovations to expand its integrated diabetes management solutions with mySugr

NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing. Inkef Capital and Roche Venture Fund join investor syndicate

IDEAYA Biosciences Raises $94 Million Crossover Series B Financing

Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs for Autoimmune and Inflammatory Diseases

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology

Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain

mySugr joins the Roche Family

Aileron Therapeutics Announces Pricing of Initial Public Offering

Senseonics Announces Pricing of $41 Million Underwritten Offering of Common Stock

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

CiVi Biopharma Receives Worldwide Exclusive License to Develop a Novel, RNA Targeted Drug Against PCSK-9

Tioma Therapeutics Announces $86 Million Series A Financing

Viewics Secures $10.5 Million in Capital, Closes Funding to Bring Advanced Analytics to Healthcare

Omicia Raises $23 Million in Series B Funding

Purigen Biosystems Receives $18.2M in Series A Financing led by 5AM Ventures and Roche Venture Fund

Second Genome Secures $42.6 Million in Series B Financing Led by Pfizer Venture Investments and Roche Venture Fund

Lumos Pharma raises $34 million in Series B financing